Naproxen: Nursing Drug Guide, GI Bleeding, Renal Risk & NCLEX Review
Aleve and Naprosyn stay in the body far longer than ibuprofen—duplicate NSAID doses can overlap for days. Before every dose, reconcile home Aleve with hospital orders, screen for aspirin-sensitive asthma, and watch for GI bleeding and rising creatinine when naproxen stacks with warfarin, ACE inhibitors, or diuretics.
NSAIDs including naproxen increase the risk of serious cardiovascular thrombotic events (myocardial infarction and stroke) and serious GI adverse events (bleeding, ulceration, perforation), which can be fatal. Naproxen is contraindicated for peri-operative pain in CABG surgery and in patients with aspirin-sensitive asthma or prior serious NSAID reactions. With a plasma half-life of about 12 to 17 hours, naproxen accumulates and overlaps easily when patients also take home Aleve, hospital ibuprofen, or other NSAIDs—raising preventable acute kidney injury and GI bleeding risk. Naproxen-containing products are not recommended in moderate to severe renal impairment (creatinine clearance <30 mL/min) per labeling. Highest-risk patients include older adults on warfarin, those with heart failure, and prior peptic ulcer or GI bleeding. Use the lowest effective dose for the shortest duration and escalate immediately for melena, hematemesis, oliguria, chest pain, or stroke symptoms.
📋 Contents
⚡ Quick facts
💡 Key takeaway
Before every naproxen dose, confirm no duplicate NSAID exposure (including home Aleve or hospital ibuprofen), verify aspirin-sensitive asthma and NSAID allergy history, and assess for GI bleeding, oliguria, and cardiovascular red flags—remember naproxen’s long half-life means yesterday’s Aleve still counts today.
Most common brand names
Naproxen is available as naproxen tablets (250 mg, 375 mg, 500 mg) and naproxen sodium tablets (275 mg, 550 mg). OTC Aleve and store brands typically provide 220 mg naproxen sodium (about 200 mg naproxen) with BID dosing on the label. Prescription brands include Naprosyn, Anaprox, and Naprelan. Naproxen sodium is absorbed more rapidly for acute pain; naproxen base has a slower onset per labeling. Patients often say “Aleve” while the MAR lists generic naproxen—reconcile strength, salt form, and total 24-hour NSAID load.
Do not confuse naproxen with acetaminophen (different toxicity profile) or with other NSAIDs (ibuprofen, ketorolac, meloxicam, celecoxib) when reconciling therapy. Because naproxen persists 12–17 hours, overlapping ibuprofen or a second Aleve dose is a common source of preventable harm.
Why we give it — Indications
Naproxen is a propionic-acid NSAID that inhibits cyclooxygenase, reducing prostaglandin-mediated pain and inflammation. Per labeling, naproxen and naproxen sodium are indicated for rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, juvenile arthritis, acute gout, bursitis, tendinitis, primary dysmenorrhea, and general pain. Nurses must match salt form (naproxen vs naproxen sodium), BID versus PRN schedules, and ensure total daily dose from all naproxen and other NSAID sources stays within prescriber and labeling limits.
| Use | Detail |
|---|---|
| Rheumatoid arthritis | Relief of signs and symptoms of rheumatoid arthritis; typical starting dose 250 mg BID to 500 mg BID naproxen per labeling. |
| Osteoarthritis | Relief of signs and symptoms of osteoarthritis. |
| Mild to moderate pain | Acute pain: naproxen sodium 550 mg then 550 mg q12h or 275 mg q6–8h PRN; initial daily total not to exceed 1375 mg naproxen sodium, then 1100 mg/day per labeling. |
| Acute gout | 750 mg naproxen then 250 mg q8h until attack subsides; naproxen sodium 825 mg then 275 mg q8h per labeling (gout flare pathway). |
| Ankylosing spondylitis | Same RA/OA dosing framework; monitor GI and renal risk with chronic BID therapy. |
On a small screen, swipe or scroll sideways to see the full table.
How it works
Naproxen inhibits cyclooxygenase, decreasing prostaglandin synthesis involved in pain and inflammation. Like other NSAIDs, it carries a boxed warning for serious cardiovascular thrombotic events and serious GI bleeding. Naproxen is well absorbed; elimination half-life is about 12 to 17 hours, with steady state in 4 to 5 days—so duplicate NSAID doses from different products can stack. Onset of relief may begin within 30 minutes with naproxen sodium and within about 1 hour with naproxen base per labeling. NSAIDs may reduce renal perfusion when combined with furosemide or ACE inhibitors such as enalapril.
Dosing overview
Use the lowest effective dose for the shortest duration consistent with treatment goals. Verify indication, renal function (naproxen is not recommended if creatinine clearance <30 mL/min), concurrent anticoagulant or diuretic therapy, and all other NSAID sources before administration. Chronic RA/OA may use 250–500 mg naproxen BID; up to 1500 mg/day for limited periods up to 6 months when higher anti-inflammatory effect is required per labeling.
Administration tip: If GI complaints occur, administer with meals or milk per labeling.
Missed dose: If a scheduled dose is missed, give when remembered unless the next dose is due soon—do not double doses. For PRN regimens, do not exceed daily maximum per prescriber order and labeling.
Onset, peak, duration, and half-life
| Parameter | Value | Nursing relevance |
|---|---|---|
| Onset | Pain relief may begin within ~30 min (naproxen sodium) or ~1 h (naproxen) per labeling | Reassess with structured pain assessment after appropriate interval |
| Peak | Plasma levels vary by formulation; bioavailability ~95% | Do not assume all naproxen products are interchangeable when switching forms |
| Half-life | About 12–17 hours; steady state in 4–5 days | Yesterday’s Aleve still contributes—critical for duplicate NSAID checks |
| Duration | Supports BID chronic regimens and less-frequent acute dosing | Do not add ibuprofen, ketorolac, or second naproxen while therapy continues |
On a small screen, swipe or scroll sideways to see the full table.
Before you give it — Safety check
Pretreatment checks
- Perform medication reconciliation—screen for duplicate NSAIDs, aspirin, anticoagulants, ACE inhibitors, ARBs, and diuretics
- Review allergy history: naproxen, aspirin/NSAID reactions, aspirin-sensitive asthma, prior serious NSAID skin reactions
- Assess cardiovascular history, blood pressure, edema, renal function (BUN/creatinine), and prior GI bleeding or peptic ulcer disease
- Confirm surgical plan—hold per protocol before CABG; NSAIDs are contraindicated for CABG pain
Contraindications
- Known hypersensitivity to naproxen or naproxen sodium
- History of asthma, urticaria, or allergic-type reactions after aspirin or other NSAIDs
- Use in the setting of coronary artery bypass graft (CABG) surgery
- Prior serious skin reactions to NSAIDs (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis) per labeling warnings
Important interactions
| Drug / class | Effect | Nursing action |
|---|---|---|
| Warfarin / anticoagulants | Increased bleeding risk; NSAIDs may affect anticoagulant control | Monitor INR and bleeding; report melena, hematuria, or bruising when combined with warfarin |
| Other NSAIDs / aspirin | Additive GI bleeding and cardiovascular risk; aspirin may reduce naproxen efficacy | Do not administer duplicate NSAID therapy without prescriber intent; clarify low-dose aspirin plans |
| ACE inhibitors / ARBs / diuretics | NSAIDs may reduce antihypertensive effect and worsen renal function in susceptible patients | Monitor blood pressure, weight, edema, and renal trends on basic metabolic panel |
| Lithium / methotrexate / digoxin | NSAIDs may increase serum levels or toxicity of these agents per NSAID class labeling | Flag to pharmacy; monitor levels and toxicity symptoms per institutional protocol |
| Ibuprofen / home Aleve overlap | Additive GI bleeding and renal injury—naproxen’s 12–17 hour half-life prolongs overlap with other NSAIDs | Hold duplicate NSAID doses; count home Aleve taken within prior 24–48 hours before hospital doses |
On a small screen, swipe or scroll sideways to see the full table.
Administration
Oral tablets: Naproxen 250 mg, 375 mg, 500 mg; naproxen sodium 275 mg and 550 mg (550 mg sodium ≈ 500 mg naproxen plus 50 mg sodium). Swallow with water; may take with food or milk if GI upset occurs per labeling.
OTC counseling: Many patients self-treat with Aleve at home—always ask about OTC naproxen sodium during admission. Because of the long half-life, a missed reconciliation of home Aleve can overlap with hospital doses for more than one day.
- Confirm home OTC NSAIDs, low-dose aspirin, and herbal antiplatelet supplements are documented after reconciliation
- Document indication, dose, route, time, and pain score before and after PRN doses
- Ensure fall-risk precautions in older adults with orthostatic symptoms, especially when bleeding or anemia develops
Cardiovascular and GI risks increase with higher cumulative daily doses and longer duration. Count all naproxen sources and overlapping NSAIDs—scheduled doses, PRN doses, and home Aleve—before administering. Reconcile whether naproxen is still needed at each care transition; consider shorter half-life NSAIDs only when prescriber/pharmacy directs.
Expected therapeutic response
- Improved pain score or joint stiffness with functional mobility gains in arthritis
- Reduced swelling and tenderness on joint exam when inflammation is present
- No new GI bleeding, blood pressure elevation, edema, or renal function decline while therapy continues
Red flags — Stop and act
Hold naproxen and escalate immediately when serious NSAID complications are suspected. Because of the long half-life, effects may persist after the last dose—still hold further NSAIDs and notify the team.
- Black stool, hematemesis, coffee-ground emesis, or severe abdominal pain suggesting GI bleeding
- Chest pain, sudden weakness, facial droop, slurred speech, or other stroke or MI symptoms
- New or worsening dyspnea, rapid weight gain, or peripheral edema in patients with heart failure
- Decreased urine output, rising creatinine, or hyperkalemia suggesting acute kidney injury
- Urticaria, facial swelling, wheezing, or anaphylaxis after a dose
- Jaundice, dark urine, or persistent nausea with rising AST/ALT on liver function tests
Adverse effects
| Adverse effect | Frequency / severity | Nursing response |
|---|---|---|
| Dyspepsia, abdominal pain, diarrhea | Common in arthritis trials | Assess for bleeding vs irritation; hold and notify if severe or accompanied by melena |
| Peripheral edema, hypertension | Common; may worsen heart failure | Monitor weight, blood pressure, and lung sounds; notify if decompensation suspected |
| Serious GI bleeding / perforation | Serious; boxed warning | Hold NSAID, obtain hemoglobin, notify prescriber, prepare for urgent GI evaluation |
| MI / stroke | Serious; boxed warning | Hold dose, obtain vital signs and ECG per protocol, activate emergency pathway for acute symptoms |
| Renal impairment | Serious in susceptible patients | Monitor intake/output and BMP; hold if acute kidney injury develops |
| Hepatotoxicity | Serious; uncommon | Monitor LFTs when ordered; discontinue if persistent abnormalities or clinical hepatitis |
| Serious skin reactions / anaphylaxis | Rare but potentially fatal | Stop permanently; treat hypersensitivity per protocol; document allergy |
On a small screen, swipe or scroll sideways to see the full table.
Overdose, toxicity, and antidote
Significant naproxen overdosage may cause lethargy, dizziness, drowsiness, epigastric pain, nausea, vomiting, transient liver function changes, hypoprothrombinemia, renal dysfunction, or metabolic acidosis per labeling. GI bleeding can occur; hypertension, acute renal failure, respiratory depression, and coma may occur but are rare. Naproxen sodium may produce high early blood levels because of more rapid absorption. Convulsions have been reported in a few patients—it is not known whether they were drug-related. Life-threatening dose is not established in labeling.
Management
- No specific antidote—manage with symptomatic and supportive care per NSAID overdose guidance
- Emesis and/or activated charcoal (60–100 g adults; 1–2 g/kg children) may be indicated within about 4 hours of ingestion with symptoms or after large overdose per labeling
- Hemodialysis does not significantly lower naproxen plasma concentration because of high protein binding
- Forced diuresis, urine alkalinization, or hemoperfusion may not be useful due to high protein binding—monitor airway, GI bleeding, and renal function
Contact local poison control or medical toxicology services for overdose guidance per facility protocol and local emergency guidance.
Look-alike / sound-alike and error prevention
- Naproxen vs naproxen sodium—550 mg sodium delivers 500 mg naproxen; 275 mg sodium ≈ 250 mg naproxen—do not double-count salt forms
- Naproxen vs ibuprofen / ketorolac—all are NSAIDs; naproxen’s long half-life makes overlap especially dangerous
- Naproxen vs acetaminophen—patients confuse Aleve with Tylenol; verify active ingredient before PRN doses
- Duplicate NSAID therapy—scheduled naproxen plus home Aleve or hospital ibuprofen is a common inpatient error
- Aleve PM and combination products—may contain diphenhydramine plus naproxen sodium; review full ingredient list on reconciliation
Practical bedside notes
| Topic | Bedside guidance |
|---|---|
| Food timing | May take with or without food; offer food or milk if GI upset occurs per labeling. |
| OTC overlap | Ask specifically about Aleve, Naprosyn, and menstrual pain products—patients may not report them as “medications.” |
| Anticoagulant patients | Prioritize bleeding assessments and INR trends at each visit when warfarin is co-ordered. |
| Diuretic / ACE inhibitor patients | Track weight, blood pressure, intake/output, and creatinine—NSAID-induced AKI can develop within days. |
| Perioperative | Contraindicated for peri-operative CABG pain; hold per surgical NSAID protocols for other procedures. |
| Ask pharmacy when | Unclear total daily NSAID load, interaction with lithium or methotrexate, or whether to switch to non-NSAID analgesia in high-risk patients. |
On a small screen, swipe or scroll sideways to see the full table.
High-risk populations
| Population | Considerations |
|---|---|
| Older adults | Higher risk of GI bleeding, renal dysfunction, and cardiovascular events—use lowest dose, monitor closely, and avoid long duration without clear benefit. |
| Prior peptic ulcer / GI bleeding | Significantly increased risk of serious GI events; coordinate gastroprotection and prescriber risk-benefit discussion before restarting NSAIDs. |
| Heart failure / cardiovascular disease | Avoid in severe heart failure unless benefit outweighs risk; monitor blood pressure, edema, and symptoms of decompensation. |
| Renal impairment / dehydration | NSAIDs may worsen renal perfusion—avoid in advanced renal disease; monitor creatinine and electrolytes when ACE inhibitors or diuretics are co-prescribed. |
| Pregnancy | Avoid in late pregnancy (ductus arteriosus closure) per labeling. Pregnancy Category C—use only if potential benefit justifies risk; adequate well-controlled studies in pregnant women are not available. |
| Lactation | Labeling notes naproxen in milk at ~1% of peak plasma and recommends avoiding use in nursing mothers; LactMed notes low levels but prefers other NSAIDs for newborns/preterm infants because of long half-life. |
On a small screen, swipe or scroll sideways to see the full table.
Monitoring and documentation
Monitor
- Pain and function using structured pain assessment and mobility goals
- GI status—stool color, hemoglobin trend, and symptoms of bleeding or ulcer
- Blood pressure, weight, edema, and heart failure symptoms
- Renal function and electrolytes on BMP when diuretics, ACE inhibitors, or ARBs are co-administered
- INR and bleeding signs when anticoagulants are used
- LFTs when hepatic risk factors or symptoms are present
Document
- Dose, route, time, indication, and pain score response for PRN doses
- Allergy verification (NSAID, aspirin-sensitive asthma, prior serious skin reaction)
- Patient education on bleeding, cardiovascular symptoms, and when to seek urgent care
- Hold parameters communicated to patient and on the MAR per institutional policy
Patient teaching
- Take exactly as prescribed—do not combine with Aleve, ibuprofen, ketorolac, or other NSAIDs unless your prescriber directs you; naproxen lasts longer in the body than ibuprofen
- Report black or bloody stools, vomiting blood, severe stomach pain, chest pain, shortness of breath, sudden weakness, facial swelling, or rash immediately
- NSAIDs can raise blood pressure and cause swelling—report rapid weight gain or ankle swelling
- Tell all clinicians you take naproxen before surgery, dental procedures, or new prescriptions
- If you use topical gel, wash hands after application and keep the medicated area away from infants’ skin and eyes
- Pregnancy planning: discuss risks with your prescriber—avoid late-pregnancy use per labeling
The Hold Rule
Do not give and contact the prescriber/pharmacist when:
- Known naproxen or NSAID hypersensitivity; aspirin-sensitive asthma history; moderate–severe renal impairment (CrCl <30 mL/min) unless prescriber documents exceptional benefit
- Suspected GI bleeding, melena, hematemesis, or severe abdominal pain
- Chest pain, stroke symptoms, or peri-CABG period when NSAIDs are contraindicated
- Acute kidney injury, oliguria, or rapidly rising creatinine while on NSAID plus diuretic/ACE inhibitor
- Supratherapeutic INR or active bleeding on anticoagulation without prescriber clearance
- Duplicate NSAID order would result from administering the scheduled dose (including home Aleve or hospital ibuprofen within overlap window)
- Late pregnancy (avoid NSAIDs that may cause ductus arteriosus closure) unless prescriber documents exceptional benefit
Hold parameters may vary by institutional protocol. Follow prescriber orders, pharmacy guidance, and facility policy.
Clinical practice integration and workflow
Naproxen feels routine because Aleve is OTC—but the 12–17 hour half-life makes duplicate-NSAID errors especially dangerous. Build Aleve reconciliation, GI bleeding screens, and renal trend review into every administration pass, especially for older adults on anticoagulants, ACE inhibitors, and diuretics.
1. Check-before-you-give protocol
- Right patient, drug, dose, route, time—and no duplicate NSAID on the MAR, home Aleve list, or overlapping ibuprofen
- Allergy screen includes NSAID reactions and aspirin-sensitive asthma
- Bleeding assessment and stool color when anticoagulated or prior PUD
- Blood pressure and weight trend when heart failure or diuretics are present
2. High-alert and safety badge
NSAID boxed warning — cardiovascular and GI riskTreat naproxen with NSAID safety discipline: lowest dose, shortest duration, count long half-life overlap, and immediate hold for bleeding or chest pain.
3. Clinical workflow: hold and question rules
- If the patient reports black stools while on naproxen and warfarin, hold the dose and notify the prescriber before the next administration
- If naproxen is ordered BID, confirm the patient did not take Aleve this morning at home
- Reconcile chronic home Aleve at discharge—ensure patients know BID limits and when to avoid stacking NSAIDs
4. Critical teach-back questions
- “Which over-the-counter pain medicines should you avoid while taking prescription naproxen?” (Patient should name Aleve/ibuprofen/other NSAIDs and know acetaminophen is a different drug unless prescriber directs otherwise.)
- “What bleeding or heart symptoms mean you should seek care immediately?” (Black stool, vomiting blood, chest pain, sudden weakness, trouble breathing.)
5. Care coordination
Pharmacist: Review anticoagulant interactions, CYP2C9 status, hepatic dosing, duplicate NSAID therapy, and gastroprotection needs
Prescriber: Notify for GI bleeding, chest pain, rising creatinine, hypertensive crisis, or need for alternative analgesia in high-risk patients
🧠 Quick mental checklist
- Is the patient taking any other NSAID, aspirin, home Aleve, or hospital ibuprofen besides this order?
- Any aspirin-sensitive asthma, NSAID allergy, or prior serious NSAID skin reaction?
- Any black stool, anemia, or abdominal pain while on naproxen?
- On warfarin or anticoagulant—when was INR last checked?
- Creatinine, blood pressure, and intake/output trend acceptable before I give this dose?
Naproxen NCLEX practice questions
Practice NCLEX-style clinical judgment practice for naproxen using a tabbed inpatient case (MAR, labs, I&O, nursing notes), then priority action, cue recognition, trend interpretation, ordered escalation steps, documentation cloze, and matrix urgency sorting—recognise long half-life duplicate NSAID risk → analyse renal/GI trends → prioritise holds → act → evaluate outcomes.
Select a tab to view MAR, labs, I&O, and nursing note details for this case.
- Naproxen 500 mg PO BID — 0800 given; 2000 due
- Lisinopril 20 mg PO daily — given 0800
- Furosemide 40 mg PO daily — given 0800
- Warfarin 5 mg PO daily — given 1800 yesterday; INR due today
- Acetaminophen 650 mg PO q6h PRN — not given in last 24 h
- No other scheduled NSAID on MAR besides naproxen BID
- Admission: Hgb 13.2 g/dL, Hct 39%, platelets 225 ×109/L, INR 2.0, BUN 24 mg/dL, creatinine 1.1 mg/dL
- Today 1400: INR 2.9 (goal 2–3); Hgb 11.4 g/dL (was 12.3 g/dL yesterday); BUN 32 mg/dL; creatinine 1.6 mg/dL; K+ 5.1 mEq/L
- Stool guaiac pending after melena report
- Intake: ~1200 mL oral fluids; no IV fluids
- Output: 450 mL urine (normally ~1500 mL/day); last void 6 hours ago per nursing note
- Weight up 1.8 kg in 48 h; bilateral ankle edema 2+
- 0800 BP 132/78; 1400 BP 102/64 with dizziness on standing
- 74-year-old with osteoarthritis; history of peptic ulcer disease 3 years ago; reports daily Aleve 220 mg BID at home (reconciled today—not on admission list)
- 1300: Patient reports “black, tarry” stools ×2 today; denies severe abdominal pain; increasing fatigue
- 1330: Nurse held 1400 naproxen and warfarin pending prescriber call
- 1400: Reviewing case tabs before escalation
Answer key & rationale
Frequently asked questions
Why is naproxen’s long half-life a nursing safety priority?
Naproxen has an elimination half-life of about 12 to 17 hours with steady state in 4 to 5 days per labeling. That means home Aleve taken yesterday can still overlap with today’s hospital naproxen or ibuprofen, increasing GI bleeding and renal injury risk. Always reconcile OTC naproxen sodium and count total NSAID exposure across a 24- to 48-hour window.
When should a nurse hold naproxen and contact the prescriber or pharmacist?
Hold for suspected GI bleeding, chest pain or stroke symptoms, acute kidney injury or oliguria, NSAID hypersensitivity, aspirin-sensitive asthma, CABG peri-operative period, creatinine clearance below 30 mL/min unless prescriber documents benefit, or INR/bleeding concerns with warfarin. Also hold if duplicate NSAID therapy would occur from hospital naproxen plus home Aleve, ibuprofen, or ketorolac.
Can naproxen be used with warfarin?
NSAIDs including naproxen increase bleeding risk and GI toxicity may be synergistic with anticoagulants per class labeling. Monitor INR and bleeding closely when combined with warfarin. Report melena, bruising, or supratherapeutic INR promptly—hold naproxen while bleeding is evaluated.
What is the maximum daily dose of naproxen for chronic arthritis?
Typical chronic RA/OA dosing is 250 to 500 mg naproxen twice daily per labeling. Dose may be increased to 1500 mg/day for limited periods up to 6 months when greater anti-inflammatory effect is required. Acute pain with naproxen sodium should not exceed 1100 mg naproxen sodium per day after the first day per labeling. Always include OTC Aleve when calculating total exposure.
Is naproxen safe during pregnancy or breastfeeding?
Avoid naproxen in late pregnancy because NSAIDs may cause premature closure of the ductus arteriosus per labeling (Pregnancy Category C). Naproxen is detected in breast milk at low levels; labeling recommends avoiding use in nursing mothers. LactMed notes low milk levels but prefers shorter half-life NSAIDs for newborns and preterm infants when alternatives exist.
What is the treatment for naproxen overdose?
There is no specific antidote per labeling. Provide symptomatic and supportive care; consider emesis or activated charcoal within about 4 hours of symptomatic ingestion. Hemodialysis is unlikely to lower naproxen levels significantly because of protein binding. Monitor airway, GI bleeding, and renal function. Contact local poison control or medical toxicology services per facility protocol.
References
-
U.S. National Library of Medicine. Naproxen and naproxen sodium tablets, USP — Full prescribing information. DailyMed.https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27ab4f1a-2f2b-150c-e054-00144ff8d46c
-
U.S. Food and Drug Administration. FDA Drug Safety Communication: FDA strengthens warning that NSAIDs increase heart attack and stroke risk.https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-prescription-nsaids-increase-heart-attack-stroke-risk
-
Drugs and Lactation Database (LactMed). Naproxen. Bethesda (MD): National Institute of Child Health and Human Development.https://www.ncbi.nlm.nih.gov/books/NBK501044/
Review and transparency
This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.
Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.